Presented by Cello Health BioConsulting, now part of Lumanity


  • Joel Sandler, PhD, Principal and Practice Head


  • Debora Barton, MD, CMO, Carisma Therapeutics
  • Charles Nicolette, PhD, CEO, CoImmune Inc.
  • Kimberly Noonan, PhD, MPH, EVP, CSO and Founder, WindMIL Therapeutics

Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry, investor, and oncologist communities alike. A fundamental but often vaguely understood component of emerging cell therapy platforms is the cell itself. In addition to peripherally-derived T-cells found in branded CAR-T products (Novartis’s Kymriah and Gilead’s Yescarta), additional cell-types are being developed as the foundation of different cell-type platforms.

But why should investors and Pharma partners deploy scarce resources to develop novel cell-types? Can they unlock value and address shortcomings of first-mover CAR-T brands? Can they be delivered as truly ‘off-the-shelf’ products? Can they reproducibly address solid tumors?

In this, the second installment in the Novel Cell-Types whitepaper and webinar series, we will explore the role of engineered macrophages (CAR-Ms), cytokine-induced killer cells (CAR-CIKs), and marrow-infiltrating lymphocytes (MILs, CAR-MILs), and the respective companies pioneering each of them. Please join us for what promises to be a provocative discussion as we attempt to answer some of these questions and explore the overlay between the science, value proposition, and strategic positioning of emerging novel cell-type platforms.